Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

valganciclovir 450 MG Oral Tablet

Known as: VALGANCICLOVIR HCL 450MG TAB, valGANciclovir HCl 450 MG Oral Tablet, VALGANCICLOVIR HYDROCHLORIDE 450 mg ORAL TABLET, FILM COATED 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
Cytomegalovirus (CMV) outcomes with valganciclovir prophylaxis in renal transplant recipients experiencing delayed graft function… Expand
2018
2018
Cytomegalovirus (CMV) remains an important pathogen in solid organ transplant patients. 
Highly Cited
2012
Highly Cited
2012
Background. Cytomegalovirus (CMV) prevention can be achieved by prophylaxis or preemptive therapy. We performed a prospective… Expand
Highly Cited
2010
Highly Cited
2010
BACKGROUND Cytomegalovirus (CMV) is the most prevalent opportunistic infection after lung transplantation. Current strategies do… Expand
Highly Cited
2008
Highly Cited
2008
Abstract:  Background:  Valganciclovir prophylaxis is reportedly associated with a low incidence of ganciclovir‐resistant… Expand
2005
2005
SummaryBACKGROUND: The most common opportunistic viral pathogen after lung transplantation is cytomegalovirus (CMV). Oral… Expand
  • table 1
Highly Cited
2004
Highly Cited
2004
We investigated the emergence of cytomegalovirus (CMV) ganciclovir-resistance mutations in 301 high-risk solid-organ transplant… Expand
  • table 1
  • table 2
Highly Cited
2003
Highly Cited
2003
The clinical patterns and predictors of cytomegalovirus (CMV) disease in kidney and/or pancreas transplant patients on… Expand